• Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 Years — United States, July–December 2021 Cite CITE Title : Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 Years — United States, July–December 2021 Personal Author(s) : Zambrano, Laura D.;Newhams, Margaret M.;Olson, Samantha M.;Halasa, Natasha B.;Price, Ashley M.;Boom, Julie A.;Sahni, Leila C.;Kamidani, Satoshi;Tarquinio, Keiko M.;Maddux, Aline B.;Heidemann, Sabrina M.;Bhumbra, Samina S.;Bline, Katherine E.;Nofziger, Ryan A.;Hobbs, Charlotte V.;Bradford, Tamara T.;Cvijanovich, Natalie Z.;Irby, Katherine;Mack, Elizabeth H.;Cullimore, Melissa L.;Pannaraj, Pia S.;Kong, Michele;Walker, Tracie C.;Gertz, Shira J.;Michelson, Kelly N.;Cameron, Melissa A.;Chiotos, Kathleen;Maamari, Mia;Schuster, Jennifer E.;Orzel, Amber O.;Patel, Manish M.;Campbell, Angela P.;Randolph, Adrienne G.; Corporate Authors(s) : CDC COVID-19 Response Team. Published Date : January 7, 2022 Series : MMWR. Morbidity and Mortality Weekly Report ; v. 71, early release, January 7, 2022 URL : https://stacks.cdc.gov/view/cdc/113210 Zambrano, Laura D. et al. (2022). Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 Years — United States, July–December 2021. 71 Zambrano, Laura D. et al. "Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 Years — United States, July–December 2021" 71 (2022) Zambrano, Laura D. et al. "Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 Years — United States, July–December 2021" vol. 71, 2022 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 463.40 KB] Personal Author: Zambrano, Laura D. ; Newhams, Margaret M. ... January 7, 2022 | MMWR. Morbidity and Mortality Weekly Report ; v. 71, early release, January 7, 2022 Description: What is already known about this topic? The Pfizer-BioNTech vaccine, currently authorized for persons aged ≥5 years, provides a high level of protec... File Type: [PDF - 463.40 KB] File Type: [PDF - 463.40 KB] Deaths related to 2009 H1N1 influenza among american Indian/Alaska Natives (AI/ANs) — 12 states, 2009 Cite CITE Title : Deaths related to 2009 H1N1 influenza among american Indian/Alaska Natives (AI/ANs) — 12 states, 2009 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : December 18, 2009 Series : Novel H1N1 flu : international situation update ; August 14, 2009 URL : https://stacks.cdc.gov/view/cdc/113186 Journal Title : Human Influenza A (H1N1), 2009 Centers for Disease Control and Prevention (U.S.) (2009). Deaths related to 2009 H1N1 influenza among american Indian/Alaska Natives (AI/ANs) — 12 states, 2009. Centers for Disease Control and Prevention (U.S.) "Deaths related to 2009 H1N1 influenza among american Indian/Alaska Natives (AI/ANs) — 12 states, 2009" (2009) Centers for Disease Control and Prevention (U.S.) "Deaths related to 2009 H1N1 influenza among american Indian/Alaska Natives (AI/ANs) — 12 states, 2009" , 2009 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 197.62 KB] : Centers for Disease Control and Prevention (U.S.) December 18, 2009 | Novel H1N1 flu : international situation update ; August 14, 2009 Description: December 18, 2009 11:30 AM ET File Type: [PDF - 197.62 KB] File Type: [PDF - 197.62 KB] Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021 Cite CITE Title : Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021 Personal Author(s) : Barrett, Catherine E.;Koyama, Alain K.;Alvarez, Pablo;Chow, Wilson;Lundeen, Elizabeth A.;Perrine, Cria G.;Pavkov, Meda E.;Rolka, Deborah B.;Wiltz, Jennifer L.;Bull-Otterson, Lara;Gray, Simone;Boehmer, Tegan K.;Gundlapalli, Adi V.;Siegel, David A.;Kompaniyets, Lyudmyla;Goodman, Alyson B.;Mahon, Barbara E.;Tauxe, Robert V.;Remley, Karen;Saydah, Sharon; Corporate Authors(s) : CDC COVID-19 Emergency Response Team.;National Center for Chronic Disease Prevention and Health Promotion (U.S.)Division of Diabetes Translation.; Published Date : January 7, 2022 Series : MMWR. Morbidity and Mortality Weekly Report ; v. 71, early release, January 7, 2022 URL : https://stacks.cdc.gov/view/cdc/113211 Barrett, Catherine E. et al. (2022). Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021. 71 Barrett, Catherine E. et al. "Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021" 71 (2022) Barrett, Catherine E. et al. "Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021" vol. 71, 2022 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 266.44 KB] Personal Author: Barrett, Catherine E. ; Koyama, Alain K. ... January 7, 2022 | MMWR. Morbidity and Mortality Weekly Report ; v. 71, early release, January 7, 2022 Description: What is already known about this topic? SARS-CoV-2 infection is associated with worsening of diabetes symptoms, and persons with diabetes are at incre... File Type: [PDF - 266.44 KB] File Type: [PDF - 266.44 KB]

More +